Lexology December 23, 2024
Earlier this week, efforts to reduce U.S. reliance on biotechnology companies in China stalled when the BIOSECURE Act (“BIOSECURE” or the “Act”) was left out of this week’s continuing resolution (CR). As a result, BIOSECURE will not be enacted into law this year. Industry and observers had been watching to see if BIOSECURE would be included in the year-end legislative package, which could have served as a stopgap measure to fund the federal government through early next year. The CR was the last potential vehicle for enactment after BIOSECURE had been excluded from the National Defense Authorization Act (NDAA) for fiscal year 2025 in early December.
While Chinese contract manufacturing and development organizations (“CDMOs”), such as WuXi Biologics and WuXi...
Today's Sponsors
Today's Sponsor